About Multiple System Atrophy
Multiple system atrophy (MSA) is a rare, rapidly progressive neurodegenerative disorder characterized by alpha-synuclein accumulation in oligodendrocytes (glial cytoplasmic inclusions). It affects the autonomic nervous system, cerebellum (MSA-C subtype), and/or the nigrostriatal system (MSA-P subtype). Key features include autonomic failure (orthostatic hypotension, urogenital dysfunction), cerebellar ataxia, and parkinsonism poorly responsive to levodopa. Median survival from onset is 6-10 years.
Common Clinical Features
Clinical Trial Eligibility Tips
What to know before applying to Multiple System Atrophy trials.
Probable MSA diagnosis per second consensus criteria is typically required — document clinical phenotype (MSA-C vs MSA-P)
Levodopa response testing (non-response or minimal response) is a diagnostic confirmation marker required for enrollment
Plasma neurofilament light chain (NfL) and alpha-synuclein seed amplification assay (SAA) are emerging eligibility biomarkers
Autonomic function testing (tilt table, QSART, urodynamics) is standard at baseline and for outcome monitoring
Patient Resources
Find recruiting Multiple System Atrophy trials
Search 500,000+ studies from ClinicalTrials.gov, filtered for Multiple System Atrophy. Updated daily.